Ioflupan (123i) Rotop

Ioflupane, the active ingredient in Ioflupan (123i) Rotop, is a radiopharmaceutical presented as an injection for intravenous use. It is employed to evaluate Parkinsonian syndromes and to aid the differential diagnosis of movement disorders in adult patients.

GNH USA supplies Ioflupan (123i) Rotop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ioflupan (123i) Rotop is used in the dopaminergic imaging pathway to assess neurological disorders. - Parkinsonian syndromes: visualizes loss of presynaptic dopamine neurons to support diagnosis. - Atypical parkinsonian disorders: helps distinguish conditions such as multiple system atrophy or progressive supranuclear palsy from idiopathic Parkinson disease. - Other movement disorders: provides functional imaging to evaluate tremor, dystonia, or drug‑induced parkinsonism.

Ioflupan (123i) Rotop may cause adverse reactions related to the injection and its radioactive nature.

Common Side Effects: - Injection site pain or erythema. - Mild nausea or vomiting. - Transient headache. - Flushing or warmth sensation. - Temporary mild hypotension. - Dizziness.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis). - Significant hypotension requiring medical intervention. - Radiation‑induced skin injury at the injection site. - Seizure activity. - Pulmonary hypertension. - Cardiac arrhythmia.

Before using Ioflupan (123i) Rotop, consider the following safety measures. - Pregnancy: unknown; avoid unless clearly needed. - Breastfeeding: unknown; weigh potential risks before administration. - Renal impairment: assess renal function as clearance may be affected. - Concomitant dopamine‑affecting drugs: monitor for altered imaging results. - Radiation safety: follow local regulations for handling and disposal of radioactive material. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ioflupan (123i) Rotop can interact with other agents that influence dopamine pathways or hemodynamics.

Major Interactions (Avoid): - MAO inhibitors: may modify DAT binding and imaging accuracy. - Antipsychotics (D2 antagonists): can block tracer uptake, compromising results. - Dopamine‑transporter blockers (e.g., cocaine, methylphenidate): reduce tracer accumulation.

Moderate Interactions (Monitor Closely): - Antihypertensive drugs: may exacerbate transient hypotension after injection. - Sedatives: could mask patient discomfort during the procedure. - Contrast agents used in other imaging studies: may interfere with SPECT interpretation.